All, great thread...with all the FDA approvals in the works this year ( the board is reviewing a record amount), this could be a great sector for big swings in both directions.
Here's my hype; check out ACMI (Accumed)...has recieved 2 FDA approvals in the past week. Lagged after the first approval, announced another after the bell today, was mentioned on "Ahead of the Curve" on CNBC, and sells at $3 1/4, near it's 52-week low. The stock had been awaiting approval on it's enhanced pap-smear test for ages, and had seen heights of $6 BEFORE APPROVAL. This could be an exciting company, and more importantly, a bargain.
Here are the articles...
CHICAGO, Aug 18 (Reuter) - AccuMed International Inc said on Monday that the U.S. Food and Drug Administration had granted the company marketing clearance for its TracCell 2000 slide-mapping system for use in pap smear screening.
The TracCell device creates an electronic "map" of a glass slide's sample area and indicates where cellular material is located, AccuMed said in a statement. In doing so, the system helps those reading the slide to focus more of their attention on relevant material, the company said.
The device will be available to diagnotic laboratories in the third quarter of 1997 and will be distributed by AccuMed's direct sales force, the company added.
CHICAGO, Aug 25 (Reuter) - AccuMed International Inc said Monday it received clearance from the U.S. Food and Drug Administration to extend use of its ESP Culture System II in a new method to test for tuberculosis.
The approval allows the use of nucleic acid probes for the direct confirmation of positive ESP - myco bottle tests.
Under the new approval, when a test is positive, the specimen in the bottle can be used for the next step in the diagnostic process -- identification of the specific mycobacteria present, the company said.
This will save labor, cost and time, the company said.
Nucleic acid probe confirmation can identify TB Complex isolated from culture quickly, often in less than two hours, the company said.
AccuMed shares were up 9/32 at 3-1/4 Monday. |
